Hydroxymethylglutaryl-CoA Reductase Inhibitors

"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.

Descriptor ID	D019161
MeSH Number(s)	D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
Concept/Terms	Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl CoA Reductase Inhibitors Inhibitors, Hydroxymethylglutaryl-CoA Reductase Reductase Inhibitors, Hydroxymethylglutaryl-CoA Inhibitors, HMG-CoA Reductase Inhibitors, HMG CoA Reductase Reductase Inhibitors, HMG-CoA HMG-CoA Reductase Inhibitors HMG CoA Reductase Inhibitors Statins, HMG-CoA HMG-CoA Statins Statins, HMG CoA Inhibitors, Hydroxymethylglutaryl-CoA Hydroxymethylglutaryl-CoA Inhibitors Inhibitors, Hydroxymethylglutaryl CoA Statins Inhibitors, Hydroxymethylglutaryl-Coenzyme A Hydroxymethylglutaryl-Coenzyme A Inhibitors Inhibitors, Hydroxymethylglutaryl Coenzyme A

Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Anticholesteremic Agents [D27.505.519.186.071.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.186.071.202.370]
Enzyme Inhibitors [D27.505.519.389]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.389.370]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]
Anticholesteremic Agents [D27.505.954.557.500.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.954.557.500.202.370]

Below are MeSH descriptors whose meaning is related to "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 129 publications over 22 distinct years, with a maximum of 12 publications in 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2002	1	1	2
2003	2	0	2
2004	7	1	8
2005	2	1	3
2006	4	6	10
2007	5	2	7
2008	3	4	7
2009	5	1	6
2010	5	3	8
2011	6	2	8
2012	11	1	12
2013	2	1	3
2014	5	2	7
2015	5	3	8
2016	8	2	10
2017	8	0	8
2018	1	3	4
2019	4	1	5
2020	2	2	4
2021	3	1	4
2022	2	0	2

Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.

Santoni M, Massari F, Matrana MR, Basso U, De Giorgi U, Aurilio G, Buti S, Incorvaia L, Rizzo M, Martignetti A, Maslov D, Tawagi K, Philon E, Blake Z, Porta C, Battelli N. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. Eur J Cancer. 2022 Sep; 172:191-198.

View in: PubMed
Santoni M, Monteiro FSM, Massari F, Abahssain H, Aurilio G, Molina-Cerrillo J, Myint ZW, Zabalza IO, Battelli N, Grande E. Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Crit Rev Oncol Hematol. 2022 Aug; 176:103731.

View in: PubMed
Mack DS, Baek J, Tjia J, Lapane KL. Geographic Variation of Statin Use Among US Nursing Home Residents With Life-limiting Illness. Med Care. 2021 05 01; 59(5):425-436.

View in: PubMed
Mack DS, Hume AL, Tjia J, Lapane KL. National Trends in Statin Use among the United States Nursing Home Population (2011-2016). Drugs Aging. 2021 05; 38(5):427-439.

View in: PubMed
Boelitz K, Jirka C, Eberhardt RT, Kalish JA, Siracuse JJ, Farber A, Jones DW. Inadequate Adherence to Imaging Surveillance and Medical Management in Patients with Duplex Ultrasound-Detected Carotid Artery Stenosis. Ann Vasc Surg. 2021 Jul; 74:63-72.

View in: PubMed
Ye S, Matthan NR, Lamon-Fava S, Solano-Aguilar G, Turner JR, Walker ME, Chai Z, Lakshman S, Chen C, Dawson H, Urban JF, Lichtenstein AH. Colon transcriptome is modified by a dietary pattern/atorvastatin interaction in the Ossabaw pig. J Nutr Biochem. 2021 04; 90:108570.

View in: PubMed
Ye S, Matthan NR, Lamon-Fava S, Aguilar GS, Turner JR, Walker ME, Chai Z, Lakshman S, Urban JF, Lichtenstein AH. Western and heart healthy dietary patterns differentially affect the expression of genes associated with lipid metabolism, interferon signaling and inflammation in the jejunum of Ossabaw pigs. J Nutr Biochem. 2021 04; 90:108577.

View in: PubMed
Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 12 15; 142(24):2299-2311.

View in: PubMed
Mack DS, Baek J, Tjia J, Lapane KL. Statin Discontinuation and Life-Limiting Illness in Non-Skilled Stay Nursing Homes at Admission. J Am Geriatr Soc. 2020 12; 68(12):2787-2796.

View in: PubMed
Mack DS, Tjia J, Hume AL, Lapane KL. Prevalent Statin Use in Long-Stay Nursing Home Residents with Life-Limiting Illness. J Am Geriatr Soc. 2020 04; 68(4):708-716.

View in: PubMed

People

Explore

Similar Concepts

Top Journals